CG Oncology, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
400 Spectrum Center Drive, Suite 2040, Irvine, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66.6 M shares
Common Stock, Shares, Outstanding 66.6 M shares
Common Stock, Value, Issued 7 K USD
Weighted Average Number of Shares Outstanding, Basic 47.1 M shares +1121%
Weighted Average Number of Shares Outstanding, Diluted 47.1 M shares +1121%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 17.2 M USD +119%
General and Administrative Expense 5.79 M USD +179%
Operating Income (Loss) -22.5 M USD -131%
Nonoperating Income (Expense) 5.54 M USD +425%
Net Income (Loss) Attributable to Parent -16.9 M USD -95.4%
Earnings Per Share, Basic -0.36 USD/shares +88.8%
Earnings Per Share, Diluted -0.36 USD/shares +88.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 77.5 M USD
Marketable Securities, Current 489 M USD
Assets, Current 579 M USD
Property, Plant and Equipment, Net 77 K USD
Operating Lease, Right-of-Use Asset 368 K USD
Other Assets, Noncurrent 53 K USD
Assets 579 M USD
Accounts Payable, Current 4.66 M USD
Liabilities, Current 9.98 M USD
Operating Lease, Liability, Noncurrent 184 K USD
Liabilities 10.2 M USD
Retained Earnings (Accumulated Deficit) -147 M USD
Stockholders' Equity Attributable to Parent 569 M USD
Liabilities and Equity 579 M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -26 M USD -226%
Net Cash Provided by (Used in) Financing Activities 403 M USD
Net Cash Provided by (Used in) Investing Activities -307 M USD -291%
Common Stock, Shares Authorized 700 M shares
Common Stock, Shares, Issued 66.6 M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 69.2 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 77.5 M USD +11079%
Operating Lease, Liability 404 K USD
Payments to Acquire Property, Plant, and Equipment 12 K USD
Lessee, Operating Lease, Liability, to be Paid 411 K USD
Operating Lease, Liability, Current 220 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 59 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 187 K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.02 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7 K USD
Operating Lease, Payments 58 K USD 0%
Additional Paid in Capital 716 M USD
Depreciation, Depletion and Amortization 4 K USD 0%
Share-based Payment Arrangement, Expense 1.52 M USD +747%